The emergence of new pharmacologic agents, particularly glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), is transforming the therapeutic landscape for obesity and its related metabolic complications, in which insulin resistance represents a central pathogenic mechanism linking type 2 diabetes mellitus (T2DM), metabolic dysfunction‐associated steatotic liver disease (MASLD), and metabolic syndrome. The gene discussed is INS; the disease is type 2 diabetes mellitus.